United States Immune-Mediated Inflammatory Diseases Treatment Market was valued at USD 28 Billion in 2022 and is projected to reach USD 45 Billion by 2030, growing at a CAGR of 6.7% from 2024 to 2030.
The US Immune-Mediated Inflammatory Diseases (IMID) Treatment Market is rapidly growing due to the increasing prevalence of autoimmune diseases and a rising demand for innovative therapies. Immune-mediated inflammatory diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, require advanced treatment options that are both effective and tailored to individual patient needs. Over the past few years, the market has witnessed significant advancements with the introduction of biologics, biosimilars, and immunosuppressive therapies.
The need for specialized treatments in the IMID sector has been heightened by the continuous growth of healthcare needs in the US. With an aging population, the demand for effective immunomodulatory treatments has surged. Industries involved in pharmaceuticals and biotechnology are at the forefront of research, looking for novel ways to target immune system dysfunctions that lead to these debilitating diseases. In fact, research has shown that the immune-mediated inflammatory diseases market is expected to grow at a compound annual growth rate (CAGR) of 5-7% over the next few years, driven by innovations in biologics, biosimilars, and small molecules.
The pharmaceutical industry is particularly focused on biologics and monoclonal antibodies that target specific cytokines responsible for inflammation.
In parallel, the development of personalized medicines is also gaining traction, which ensures that treatment plans are better suited to each individual, thereby improving patient outcomes.
The increasing investment in immunology research further reflects the industry's commitment to addressing unmet medical needs and enhancing the quality of life for patients.
Additionally, there is a growing demand for more efficient and faster drug delivery systems. As a result, industries are investing in advanced drug delivery technologies, aiming to enhance the effectiveness and reduce side effects of treatments. The need for robust diagnostics, efficient supply chains, and the ability to meet regulatory standards are also crucial factors driving market growth. These requirements are reshaping how pharmaceutical companies approach the development and distribution of drugs for immune-mediated diseases.
In light of these trends, the US Immune-Mediated Inflammatory Diseases Treatment Market is witnessing increasing collaboration between biopharma companies, research institutes, and healthcare providers to meet the growing demand for advanced therapies. This trend is not only revolutionizing treatments but is also contributing to the broader healthcare landscape, leading to more personalized, accessible, and effective care for patients dealing with immune-mediated conditions.
Get an In-Depth Research Analysis of the US Immune-Mediated Inflammatory Diseases Treatment Market Size And Forecast [2025-2032]
GlaxoSmithKline
Eli Lilly
AstraZeneca
Bristol-Myers
Sanofi
Roche
Enlivex Therapeutics
Immune Pharmaceuticals
Tanabe Pharma
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US Immune-Mediated Inflammatory Diseases Treatment Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US Immune-Mediated Inflammatory Diseases Treatment Market
Autoimmune Diseases
Inflammatory Bowel Diseases
Psoriasis and Other Dermatological Conditions
Biologic Therapies
Small Molecule Drugs
Corticosteroids
Immunosuppressants
Oral Administr
Parenteral Administr
Topical Applic
Age Group
Gender
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Pharmacies
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Immune-Mediated Inflammatory Diseases Treatment Market Research Analysis
1. Introduction of the US Immune-Mediated Inflammatory Diseases Treatment Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US Immune-Mediated Inflammatory Diseases Treatment Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US Immune-Mediated Inflammatory Diseases Treatment Market, By Type
6. US Immune-Mediated Inflammatory Diseases Treatment Market, By Application
7. US Immune-Mediated Inflammatory Diseases Treatment Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US Immune-Mediated Inflammatory Diseases Treatment Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/